Interest in amyotrophic lateral sclerosis (ALS) biomarkers has grown exponentially over the
course of the last 25 years, with great hope that they might serve as tools to facilitate the …

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by
loss of upper and lower motor neurons, resulting in progressive weakness of all voluntary …

Objective To explore whether the utility of neurofilament light chain (NfL), as a biomarker to
aid amyotrophic lateral sclerosis (ALS) therapy development, would be enhanced by …

Increasing appreciation of the phenotypic and biological overlap between amyotrophic
lateral sclerosis (ALS) and frontotemporal dementia, alongside evolving biomarker evidence …

Presymptomatic amyotrophic lateral sclerosis: from character... : Current Opinion in Neurology
Presymptomatic amyotrophic lateral sclerosis: from characterization to prevention : Current …

Amyotrophic lateral sclerosis (ALS) is often considered a relatively rare disease, but risk
estimates suggest that the lifetime risk of ALS is 1: 263 for males and 1: 417 for females by …

A prodrome is an early set of symptoms, which indicates the onset of a disease; these
symptoms are often non-specific. Prodromal phases are now recognized in multiple central …

TDP-43 intracellular aggregates are a pathogenic sign of most amyotrophic lateral sclerosis
(ALS) cases. Familial ALS, brought on by TARDBP gene mutations, emphasizes the …

Background and Objectives Observational studies have demonstrated an increased
amyotrophic lateral sclerosis (ALS) risk among professional athletes in various sports. For …

Background Cognitive and behavioural dysfunction may occur in people with motor neuron
disease (MND), with some studies suggesting an association with the C9ORF72 repeat …